💊 Granules India Q3 Results: Profit Rises 28%, Margins Improve

Granules India delivered a strong Q3 performance, with net profit rising 28% YoY to ₹150 crore. Revenue increased 22% to ₹1,388 crore, driven by robust demand in the finished dosage segment. EBITDA grew 33% to ₹308 crore, with margins expanding to 22.2% from 20.3% last year, supported by an improving product mix and operational efficiency. #GranulesIndia #PharmaStocks #Q3Earnings #Healthcare #StockYardResearch